This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Good afternoon, everyone, and welcome to day four of the JPMorgan healthcare conference. I'm Mike Ulz from Geoff Meacham's biotech team here at JPMorgan. And it's my pleasure to introduce Kevin Gorman, CEO of Neurocrine.
Thank you very much, Mike, and thank you very much, JPMorgan, for the opportunity to present here at the beginning of the year. Before I get started, I direct everyone to our Safe Harbor. I will be making forward-looking statements, and I also direct you, to a more complete set of specific risks, to our recent SEC filings.
What I would like to do and start this year out, as we start every year out, is putting up right away what are the major goals that we have planned for 2012. I list them here for you today, and these are goals that add value to the company and to shareholders, and several of them are quite aggressive. I'd like to spend a couple minutes going through them.
We have a Phase II trial, two weeks in duration, placebo controlled, in our VMAT2 inhibitor program. That Phase II study is going to read out towards the end of March this year. In addition, based on having successfully completed our three months toxicology studies in rodents and dog.
We are now going to then in the middle of this year, embark on two large Phase IIb studies in tardive dyskinesia. The first of which is going to be in schizophrenic patients. The second one will then start up in bipolar and depressed patients. A stretch is going to be that we hope, if enrollment goes well, that we're going to be able to report out by the end of this year, topline data from that first TD study in schizophrenic patients.